Fact Meets Function

Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.

This peer-reviewed study demonstrates that adjunctive thymosin beta-4 (TB4) combined with standard antibiotic therapy (ciprofloxacin) not only reduces bacterial keratitis severity and accelerates wound healing, but critically also promotes corneal nerve regeneration and restores visual function—outcomes that represent significant clinical advantages beyond infection control alone. The research fills a previously unexplored gap by quantifying TB4’s impact on two often-neglected but essential determinants of long-term patient outcomes: sensory nerve recovery and functional vision restoration. For practitioners, this represents compelling evidence that TB4 adjunctive therapy addresses the full spectrum of corneal infection recovery, not just pathogen elimination.

Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function. Read Post »

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.

A new in vitro study demonstrates that KPV, one of Annular’s peptide compounds, significantly reduces fat accumulation in liver cells exposed to oleic acid, a model for non-alcoholic fatty liver disease (NAFLD). The research shows KPV works by reducing oxidative stress and regulating key fat-production pathways, specifically targeting the PPAR gamma pathway that controls fatty acid synthesis. At 100 μg/mL concentration, KPV prevented liver cell damage and normalized fat metabolism without toxicity. This provides mechanistic evidence for KPV’s potential therapeutic role in treating hepatic steatosis, the early stage of NAFLD.

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Read Post »

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.

A new in vitro study demonstrates that KPV, one of Annular’s peptide compounds, significantly reduces fat accumulation in liver cells exposed to oleic acid, a model for non-alcoholic fatty liver disease (NAFLD). The research shows KPV works by reducing oxidative stress and regulating key fat-production pathways, specifically targeting the PPAR gamma pathway that controls fatty acid synthesis. At 100 μg/mL concentration, KPV prevented liver cell damage and normalized fat metabolism without toxicity. This provides mechanistic evidence for KPV’s potential therapeutic role in treating hepatic steatosis, the early stage of NAFLD.

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Read Post »

Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype.

NMN supplementation at high doses demonstrated anti-tumor efficacy comparable to PD-1 checkpoint inhibitors in a murine mesothelioma model by reprogramming tumor-associated macrophages toward a pro-inflammatory M1 phenotype rather than enhancing T cell or NK cell responses. This represents a novel immunotherapy mechanism distinct from current checkpoint blockade strategies. The findings suggest NMN may offer an alternative or complementary cancer immunotherapy approach by modulating innate immunity through macrophage phenotype shifting.

Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype. Read Post »

Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice.

NMN supplementation restored hepatic NAD+ levels in alcohol-fed mice, which attenuated liver steatosis, inflammation, and oxidative stress through restoration of the Hamp iron-regulation pathway. The mechanism involves C/EBPα-mediated transcriptional control of Hamp expression, linking NAD+ metabolism to iron homeostasis and lipid metabolism. This identifies NMN as a targeted dietary therapeutic for alcohol-associated liver disease (ALD) with a well-characterized molecular pathway, offering practitioners a science-backed rationale for recommending NMN to patients with metabolic liver dysfunction.

Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice. Read Post »

Coordination-Driven Cu2+-Peptide Supramolecular Hydrogel-PCL Scaffold for Synergistic Antibacterial Activity and Osteogenic Regeneration in Infectious Bone Defects.

Researchers developed a copper-peptide hydrogel scaffold that combines antibacterial, antioxidant, and bone-regenerative properties for treating infected bone defects. The material showed >99% efficacy against resistant bacteria (MRSA, Pseudomonas), reduced oxidative stress, and promoted osteoblast differentiation and new bone formation in rat models. This demonstrates a metal-peptide coordination strategy relevant to GHK-Cu’s known copper-dependent mechanisms in tissue repair and antimicrobial activity.

Coordination-Driven Cu2+-Peptide Supramolecular Hydrogel-PCL Scaffold for Synergistic Antibacterial Activity and Osteogenic Regeneration in Infectious Bone Defects. Read Post »

Extracellular matrix-derived matrikines as emerging modulators of neuroinflammation and central nervous system signaling.

This review identifies matrikines—bioactive peptide fragments derived from extracellular matrix proteins—as a distinct class of neuroimmune modulators with therapeutic potential in neuroinflammation and neurodegeneration. GHK, a collagen-derived matrikine, is highlighted as a CNS-relevant compound that modulates microglial and astrocytic function, enhances neuronal survival, and may cross a compromised blood-brain barrier. The authors emphasize that matrikines represent an emerging therapeutic avenue complementary to classical immune mediators, but call for urgent human tissue studies to establish translational relevance and clinical utility.

Extracellular matrix-derived matrikines as emerging modulators of neuroinflammation and central nervous system signaling. Read Post »

Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis.

This in vitro study demonstrates that the mycotoxin deoxynivalenol (DON) causes severe renal cell damage primarily through PARP1 hyperactivation and consequent NAD+ depletion, rather than through NAMPT inhibition as previously thought. Nicotinamide (NAM) successfully rescued cells by suppressing PARP1 activity and restoring NAD+ pools, while NMN supplementation alone did not protect against DON toxicity. The findings suggest that NAD+ restoration strategies targeting PARP1 inhibition may offer therapeutic value for mycotoxin exposure, relevant to practitioners considering NAD+-supporting interventions for clients with food safety concerns or oxidative stress conditions.

Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis. Read Post »

Targeting the Gut-Brain Axis: Protective Effects of NMN in Alleviating D-Galactose-Induced Cognitive Deficits.

This peer-reviewed study demonstrates that NMN, an NAD+ precursor, protects against age-related cognitive decline in mice by reducing oxidative stress, suppressing neuroinflammation, and modulating gut microbiota composition toward butyrate-producing bacteria. The mechanism involves activation of the Nrf2/HO-1 antioxidant pathway and increased antioxidant enzyme activity in the hippocampus. These findings support NMN as a therapeutic strategy for age-related neurodegeneration via gut-brain axis modulation at doses of 300-500 mg/kg.

Targeting the Gut-Brain Axis: Protective Effects of NMN in Alleviating D-Galactose-Induced Cognitive Deficits. Read Post »

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.

This peer-reviewed analysis critically examines BPC-157’s development barriers as a pharmaceutical candidate, identifying significant unresolved challenges: no approved formulation exists, dosing regimens lack validation, and no Phase II trials have been completed despite 30+ years of preclinical research. The paper systematically addresses biopharmaceutical obstacles including physicochemical properties, pharmacokinetic-pharmacodynamic disconnects, formulation hurdles across administration routes, and regulatory/translational barriers. For practitioners and supplement brands, this represents authoritative documentation of why BPC-157 remains investigational and the specific scientific gaps between preclinical promise and clinical reality.

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Read Post »

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

A peer-reviewed rat study demonstrated that BPC-157 significantly protects against ischemia-reperfusion injury in lower limb skeletal muscle by reducing oxidative stress markers (MDA, TOS), restoring antioxidant capacity (SOD, TAS), suppressing apoptotic pathways (p53, Bax, Caspase-3), and reducing inflammatory cytokines (IL-6). The compound also partially restored angiogenic signaling (VEGF) and improved histological muscle architecture with reduced fibrosis. This positions BPC-157 as a potential therapeutic option for peripheral arterial disease complications, a significant clinical indication with clear practitioner relevance.

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Read Post »

The role of electroacupuncture in altering lipoic acid metabolism to reduce joint inflammation in rheumatoid arthritis rats.

This rat study demonstrates that low-intensity electroacupuncture reduces rheumatoid arthritis inflammation by modulating lipoic acid metabolism and copper homeostasis, with effects comparable to methotrexate. The research identifies DLAT and LIAS proteins as key metabolic targets and shows serum copper levels correlate with anti-inflammatory outcomes. The findings suggest copper-dependent peptide compounds like GHK-Cu may offer a novel therapeutic angle for RA management through metabolic pathway modulation rather than immune suppression alone.

The role of electroacupuncture in altering lipoic acid metabolism to reduce joint inflammation in rheumatoid arthritis rats. Read Post »

Scroll to Top